Pharmac is exploring options for alternative brands of oestradiol patches

Pharmac is working to ensure uninterrupted access for individuals who rely on different brands of oestradiol patches beyond December 2025. Discussions are underway with suppliers, including the maker of the Estradot brand and consumer groups representing patch users.

Pharmac’s Director of Equity and Engagement, Dr. Nicola Ngawati, highlighted that a public consultation will be conducted to gather feedback on potential next steps. This consultation will be open to key stakeholders and those who recently organised a petition, and updates will be shared on Pharmac’s website.

Dr. Ngawati assured us that multiple brands, including Estradot, will remain available during this process. Pharmac also acknowledged that while the recent feedback emphasised supply concerns, it is also about providing personal choice. A more transparent, more robust consultation process will be implemented moving forward.

For more details, visit Pharmac's website.